Drug & intervention

indacaterol

RxCUI 1114326

How to interpret these research links

Connected source records

CureCurrent currently connects this RxNorm drug concept to 39 displayed clinical trials and 10 distinct registered condition labels on this page. The links show what was studied, not whether this drug is effective or approved for those conditions. FDA-label excerpts, when available, refer to specific labeled products and may include route and formulation restrictions.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

What this record represents

IN · RxNorm

This is an RxNorm IN drug concept. Its name, formulation details and source identifiers are preserved to distinguish it from other drug records.

What this record does not establish: current marketing availability, therapeutic equivalence, safety, or official approval status. Check an up-to-date product label or a pharmacist for product-specific questions.

Inspect the RxNorm source identifier

Research activity for this drug concept

Published registry records

Study starts and current recruitment statuses across 39 distinct linked trials. This measures registered research activity, not medical effectiveness or FDA approval.

Reported start-year cohortsRegistered start year; the green segment is the subset reported as recruiting in the current snapshot. The current year may be incomplete.
All other statuses Currently recruiting
Current recruiting and other trial statusesCurrent ClinicalTrials.gov status snapshot for linked trials.
COMPLETED35 (89.7%)
WITHDRAWN2 (5.1%)
SUSPENDED1 (2.6%)
UNKNOWN1 (2.6%)

Related drug records

RxNorm name matches

These are other published drug concepts with matching brand or formulation names. They are not necessarily equivalent medicines.

indacaterol maleatePIN · CureCurrent ID 314491
indacaterol 0.075 MGSCDC · CureCurrent ID 335782
indacaterol Inhalation PowderSCDF · CureCurrent ID 342974
indacaterol 0.075 MG Inhalation PowderSCD · CureCurrent ID 314493

Molecular structure

Verified RxNorm ingredient illustration
Molecular structure illustration of indacaterol
RxNorm RxCUI 1114326 · PubChem CID 6918554 · C24H28N2O3. Verify structure at PubChem. This drawing represents the matched chemical ingredient, not necessarily a complete multi-ingredient branded product.
Clinical trials39
Recruiting0
Related conditions10
Synonyms5
Advertisement

Clinical trials

39 shown
Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPDNCT07541378 · 2024-03-11
SUSPENDED
Effect of a LAMA and a uLABA on the Methacholine Dose-response CurveNCT02953041 · 2016-10-01
COMPLETED
Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)NCT02872090 · 2016-03-01
COMPLETED
Pulmonary Gas Exchange Response to Indacaterol in COPDNCT02547558 · 2015-10-01
UNKNOWN
Indacaterol in Heart Failure Patients: Any Role on Lung Fluid RegulationNCT02598505 · 2015-09-01
COMPLETED
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of ExacerbationsNCT02418468 · 2015-04-28
COMPLETED
Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus TiotropiumNCT02257385 · 2014-10-15
COMPLETED
Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPDNCT02055352 · 2014-05-30
COMPLETED
Ultra-long Acting Bronchodilator Therapy in AsthmaticsNCT02039011 · 2014-02-01
COMPLETED
Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD PatientsNCT01727024 · 2013-04-01
COMPLETED
Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)NCT02473237 · 2013-04-01
COMPLETED
Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPDNCT01693003 · 2013-03-01
COMPLETED
Indacaterol EfectIveness In COPD Patients With Tuberculosis HistoryNCT01778062 · 2013-02-01
COMPLETED
Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active ControlNCT01715311 · 2012-11-01
WITHDRAWN
Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass ExposureNCT05506865 · 2012-09-01
COMPLETED
Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent AsthmaNCT01609478 · 2012-08-01
COMPLETED
A Single-dose Study to Investigate the Effects of 3 Different Doses of Inhaled AZD2115 in COPD PatientsNCT01498081 · 2012-03-01
COMPLETED
Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)NCT01555138 · 2012-02-01
COMPLETED
Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT01543828 · 2012-01-01
COMPLETED
Efficacy of Indacaterol 150 µg Versus FormoterolNCT01377428 · 2011-09-01
WITHDRAWN
12-week Open-label Evaluation of Efficacy and Safety of IndacaterolNCT01232894 · 2011-03-01
COMPLETED
To Determine the Relationship Between Baseline Reversibility and the Efficacy of IndacaterolNCT01272362 · 2010-04-01
COMPLETED
Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)NCT01089127 · 2010-03-01
COMPLETED
Efficacy, Safety and Pharmacokinetics of Different Regimens of IndacaterolNCT01156844 · 2010-03-01
COMPLETED
Efficacy and Safety of Different Doses of IndacaterolNCT01079130 · 2010-02-01
COMPLETED
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 WeeksNCT01068600 · 2010-01-01
COMPLETED
Effect of Indacaterol on Inspiratory Capacity (IC)NCT01012765 · 2009-11-01
COMPLETED
Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)NCT00677807 · 2008-05-01
COMPLETED
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT00669617 · 2008-04-01
COMPLETED
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active ControlNCT00615459 · 2008-02-01
COMPLETED
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00615030 · 2008-01-01
COMPLETED
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00570778 · 2007-12-01
COMPLETED
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)NCT00558285 · 2007-11-01
COMPLETED
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00557466 · 2007-10-01
COMPLETED
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent AsthmaNCT00545272 · 2007-10-01
COMPLETED
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and SalmeterolNCT00531050 · 2007-08-01
COMPLETED
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00463567 · 2007-04-01
COMPLETED
Dose Ranging Study for Indacaterol in Japanese Asthma PatientsNCT00403754 · 2006-11-01
COMPLETED
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active ControlNCT00393458 · 2006-10-01
COMPLETED

Conditions in registry-name-matched drug studies

ClinicalTrials.gov intervention names begin with this ingredient name. These are text matches, not verified RxNorm mappings, evidence of treatment efficacy, or approved indications. Different salts or formulations may be involved.

Chronic Obstructive Pulmonary Disease24 Asthma19 Chronic Obstructive Pulmonary Disease (COPD)19 COPD15 Pulmonary Disease, Chronic Obstructive3 Lung Diseases, Obstructive2 COPD (Chronic Obstructive Pulmonary Disease)1 Dyspnea1 Healthy1 Healthy Volunteers1 Heart Failure1 Hyperinflation1 Hypoxemia1 Lung Diseases1 Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis1 Persistent Asthma1 Right Cardiac Failure1 Tachycardia1

Matching published trials

Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active ControlNCT00393458 · COMPLETED
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)NCT00396604 · COMPLETED
Efficacy and Safety of Single Doses of Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) Compared to Placebo in Patients With Persistent AsthmaNCT00403637 · COMPLETED
Dose Ranging Study for Indacaterol in Japanese Asthma PatientsNCT00403754 · COMPLETED
Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00403845 · COMPLETED
Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and FormoterolNCT00422552 · COMPLETED
26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00463567 · COMPLETED
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent AsthmaNCT00529529 · COMPLETED
Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and SalmeterolNCT00531050 · COMPLETED
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via TWISTHALER® Device in Adult and Adolescent Patients With Persistent AsthmaNCT00545272 · COMPLETED
Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With AsthmaNCT00556673 · COMPLETED
Investigation of the 24 Hour Forced Expiratory Flow in 1 Second (FEV1) Profile of a Single Dose of Indacaterol/Mometasone Delivered Via the TWISTHALER® Device in Adult Patients With Persistent AsthmaNCT00557440 · COMPLETED
A Dose Ranging Trial of 4 Doses of Indacaterol Delivered Via the TWISTHALER® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00557466 · COMPLETED
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)NCT00558285 · COMPLETED
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active ControlNCT00567996 · COMPLETED
Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00570778 · COMPLETED
Safety and Tolerability of Indacaterol Maleate/Mometasone Furoate Delivered Via the Twisthaler® Device After 14 Days Treatment in Patients With Mild to Moderate AsthmaNCT00605306 · COMPLETED
Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00615030 · COMPLETED
A Crossover Study to Determine the Effect on Lung Function of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD), Using Tiotropium as an Active ControlNCT00615459 · COMPLETED
The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT00620022 · COMPLETED
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)NCT00622635 · COMPLETED
Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)NCT00624286 · COMPLETED
Tolerability of Indacaterol Salts (Maleate, Xinafoate and Acetate) in Comparison to Placebo in Patients With Mild to Moderate Persistent AsthmaNCT00624702 · COMPLETED
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)NCT00636961 · COMPLETED
Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)NCT00669617 · COMPLETED
Advertisement

Sponsors and collaborators in trials studying this drug

Links follow ClinicalTrials.gov trial associations; they do not identify the medicine's manufacturer or owner.

Novartis Pharmaceuticals 18 lead-sponsor trials · 0 collaborator trials 18 Novartis 10 lead-sponsor trials · 2 collaborator trials 12 National Institute of Respiratory Diseases, Mexico 2 lead-sponsor trials · 0 collaborator trials 2 AstraZeneca 1 lead-sponsor trial · 0 collaborator trials 1 Centre Hospitalier Universitaire de Besancon 1 lead-sponsor trial · 0 collaborator trials 1 Centro Cardiologico Monzino 1 lead-sponsor trial · 0 collaborator trials 1 GlaxoSmithKline 1 lead-sponsor trial · 0 collaborator trials 1 Hospital Clinic of Barcelona 1 lead-sponsor trial · 0 collaborator trials 1 Irmandade Santa Casa de Misericórdia de Porto Alegre 1 lead-sponsor trial · 0 collaborator trials 1 Medical University of Bialystok 1 lead-sponsor trial · 0 collaborator trials 1 University of Dundee 1 lead-sponsor trial · 0 collaborator trials 1 University of Saskatchewan 1 lead-sponsor trial · 0 collaborator trials 1 Schering-Plough 0 lead-sponsor trials · 2 collaborator trials 2 Tenovus Scotland 0 lead-sponsor trials · 1 collaborator trial 1
Advertisement

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.